Loading…
Lineage Cell Therapeutics, Inc. is projected to rise to $1.23 by 2027, a +14% move from its current price of $1.08. LCTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.05 | $1.08 | $1.11 | -0.01% |
| Aug 4 | $1.04 | $1.08 | $1.12 | -0.03% |
| Aug 5 | $1.03 | $1.08 | $1.13 | -0.04% |
| Aug 6 | $1.02 | $1.08 | $1.14 | -0.05% |
| Aug 7 | $1.02 | $1.08 | $1.15 | -0.07% |
| Aug 8 | $1.01 | $1.08 | $1.15 | -0.08% |
| Aug 9 | $1.01 | $1.08 | $1.16 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.01 | $1.08 | $1.16 | -0.09% |
| Week 2 | $0.9764 | $1.08 | $1.19 | -0.19% |
| Week 3 | $0.954 | $1.08 | $1.22 | -0.28% |
| Week 4 | $0.9354 | $1.08 | $1.24 | -0.38% |
| Week 5 | $0.9192 | $1.07 | $1.26 | -0.47% |
| Week 6 | $0.9047 | $1.07 | $1.27 | -0.56% |
| Week 7 | $0.8915 | $1.07 | $1.29 | -0.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company focuses on allogeneic cell therapy programs, including OpRegen for retinal disease and OPC1 for spinal cord injuries.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, in preclinical development for sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, in preclinical development for vision loss due to photoreceptor dysfunction or damage. The company is also developing RND1, ILT1, LCT-CON and other therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic disorders and oncology.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics, Inc. (LCTX) is trading at $1.10 per share. The stock has a market cap of $274.23M and ranks 3361 by market capitalization. The overall price outlook is depicted by the forecast as bullish in the long term, with near-term flat performance and a potential to rise toward multiple dollars per share by 2050.
Forecasts show a bullish trajectory across multiple years, with 2026 forecast at a flat level relative to current price and rising averages thereafter, culminating in a strong long-term upside implied by the forecasted maxima.
A major floor 22.8% below — a decisive break under it would weaken the trend.
The nearest floor, 4.6% below — buyers have tended to step in here.
The nearest ceiling, 25.0% above — a clean break opens room to run.
A major ceiling 58.3% above — clearing it would confirm fresh momentum.
Key LCTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LCTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.07 | Buy | $1.08 | Sell |
| MA 10 | $1.08 | Sell | $1.10 | Sell |
| MA 20 | $1.17 | Sell | $1.14 | Sell |
| MA 50 | $1.23 | Sell | $1.23 | Sell |
| MA 100 | $1.37 | Sell | $1.33 | Sell |
| MA 200 | $1.55 | Sell | $1.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.46 | Neutral |
| Stoch RSI (14) | 76.84 | Neutral |
| CCI (20) | -66.13 | Neutral |
| Williams %R (14) | -73.68 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -11.48 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 26.32 | Neutral |
| TRIX (15) | -0.56 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 39.93 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.08 | Sell |
| ADX (14) | 22.21 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bearish. RSI14 is 30, indicating bearish momentum; the 50-day moving average (SMA50) is $1.26, and the 200-day moving average (SMA200) is $1.58.
Price is at $1.10 with support at $1.10 and resistance at $1.35. The 30-day range spans from $0.9246 to $1.31, highlighting limited upside within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.03 | $1.08 | $1.33 | 0% | Neutral | |
| $0.9851 | $1.23 | $1.63 | +14% | Neutral | |
| $1.13 | $1.46 | $1.99 | +35% | Bullish | |
| $1.23 | $1.62 | $2.29 | +50% | Bullish | |
| $1.35 | $1.81 | $2.61 | +67% | Bullish | |
| $1.32 | $1.81 | $2.66 | +67% | Bullish | |
| $1.30 | $1.81 | $2.72 | +68% | Bullish | |
| $1.39 | $1.96 | $3.00 | +82% | Bullish | |
| $1.62 | $2.32 | $3.60 | +115% | Bullish | |
| $1.86 | $2.70 | $4.25 | +150% | Bullish | |
| $2.20 | $3.41 | $5.71 | +216% | Bullish | |
| $3.65 | $6.31 | $11.52 | +484% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.03 | $1.08 | $1.27 | +0.00% |
| September 2026 | $0.8753 | $1.03 | $1.26 | -4.22% |
| October 2026 | $0.8968 | $1.07 | $1.31 | +3.13% |
| November 2026 | $0.9121 | $1.09 | $1.35 | +2.26% |
| December 2026 | $0.8898 | $1.07 | $1.33 | -1.97% |
Click any year to see its month-by-month LCTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LCTX to range from $1.03 to $1.33 through 2026. The $1.08 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The LCTX price prediction for 2027 points to an average of $1.23 (low $0.9851, high $1.63) — a potential gain of +14% on today's $1.08. A consolidation phase looks the most probable path here.
In 2028, LCTX is projected to trade between $1.13 and $1.99, averaging $1.46 — a potential gain of +35% from today's $1.08. That is up +18% on the projected 2027 average. Momentum favours further upside here.
Lineage Cell Therapeutics, Inc.'s 2029 outlook centres on $1.62, within a $1.23 to $2.29 range. That is up +11% on the projected 2028 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, LCTX could reach as high as $2.61, with a base case around $1.81 and support toward $1.35 — roughly +67% from $1.08. Momentum favours further upside here.
Expect LCTX to range from $1.32 to $2.66 through 2031. The $1.81 average target implies a +67% move from current prices. That is up 0% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The LCTX price prediction for 2032 points to an average of $1.81 (low $1.30, high $2.72) — a potential gain of +68% on today's $1.08. Momentum favours further upside here.
In 2033, LCTX is projected to trade between $1.39 and $3.00, averaging $1.96 — a potential gain of +82% from today's $1.08. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Lineage Cell Therapeutics, Inc.'s 2034 outlook centres on $2.32, within a $1.62 to $3.60 range. That is up +18% on the projected 2033 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2035, LCTX could reach as high as $4.25, with a base case around $2.70 and support toward $1.86 — roughly +150% from $1.08. Buyers look set to stay in control over this stretch.
Expect LCTX to range from $2.20 to $5.71 through 2040. The $3.41 average target implies a +216% move from current prices. That is up +27% on the projected 2035 average. Momentum favours further upside here.
The LCTX price prediction for 2050 points to an average of $6.31 (low $3.65, high $11.52) — a potential gain of +484% on today's $1.08. Buyers look set to stay in control over this stretch.
Investing $1,000 in LCTX today (≈ 925.925926 LCTX) could be worth
$5,841.22
+$4,841.22 (+484%) by 2050 · US Dollar
Based on the average projected LCTX price of $6.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LCTXwould be worth at today's price.
$1,000 invested in LCTX on Jul 31, 2025 (≈ 980.392175 LCTX) would be worth
$1,058.82
+$58.82 (+5.9%) today · 1.06× · US Dollar
Based on a LCTX entry price of $1.02 vs. today's $1.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.03 | $1,048.54 | +4.9% |
| 1 month ago | $1.3 | $830.77 | -16.9% |
| 3 months ago | $1.53 | $705.88 | -29.4% |
| 6 months ago | $1.54 | $701.3 | -29.9% |
| 1 year ago | $1.02 | $1,058.82 | +5.9% |
| All time (5.0y) ago | $2.61 | $413.79 | -58.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LCTX forecast.
Our base-case forecast reaches $2.20 around 2034.
Implied market cap at $2.20: $548.46M
The multi-year forecast shows a bullish trajectory across key years. Key annual averages and ROIs include 2026 min $1.10, avg $1.10, max $1.34, ROI 0; 2027 min $0.9685, avg $1.21, max $1.60, ROI 10.2; 2028 min $1.08, avg $1.38, max $1.90, ROI 25.8; 2029 min $1.16, avg $1.53, max $2.15, ROI 39; 2030 min $1.28, avg $1.71, max $2.47, ROI 55.6. Further years show continued gains, with 2031 min $1.21, avg $1.66, max $2.44, ROI 50.6; 2032 min $1.18, avg $1.63, max $2.45, ROI 48.5; 2033 min $1.27, avg $1.79, max $2.74, ROI 63; 2034 min $1.42, avg $2.02, max $3.14, ROI 84.1; 2035 min $1.62, avg $2.34, max $3.69, ROI 113; 2040 min $1.84, avg $2.84, max $4.75, ROI 158.4; 2050 min $3.03, avg $5.22, max $9.52, ROI 374.6.
These are estimates and not guarantees; the sentiment is bullish across these years.
Tap a question to reveal the answer.
Min $1.28, Avg $1.71, Max $2.47; ROI 55.6%; sentiment bullish.
Forecasts show a bullish trajectory after 2026, with Avg prices rising to $1.71 by 2030 and ROI reaching 55.6% by 2030, $5.22 by 2050 with ROI 374.6%. However, 2026 has Avg $1.10 and ROI 0; these are estimates, not guarantees.
Yes, the 2050 forecast lists Avg $5.22 and Max $9.52 with ROI 374.6%; sentiment bullish.
Current price $1.10; market cap $274.23M; rank 3361.
RSI 14 = 30 (bearish); SMA50 = $1.26; SMA200 = $1.58; support $1.10; resistance $1.35; 30-day range $0.9246–$1.31.
Lineage Cell Therapeutics, Inc. Community Discussion
0Share your Lineage Cell Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.